A novel regulatory circuit of ATG4B and SESN3 promotes T cell leukemogenesis

Wenjuan Ma, Lei Zhang, Haixia Zhou, Xiuyan Zhang, Xiao Qin, Yan Wan, Rongyao Ma, Xiang Song, Xiaonan Zhou, Hong Liu, Bo Hu, Depei Wu, Jianrong Wang, Xiaoyan Jiang, Yun ZhaoJournal of Experimental & Clinical Cancer Research 2025 · DOI

TL;DR

Researchers have uncovered a new molecular pathway involving ATG4B and SESN3 that drives T-cell acute lymphoblastic leukemia (T-ALL). This discovery suggests that targeting ATG4B could be a promising new treatment strategy for this aggressive blood cancer.

What Problem Does This Paper Address?

T-cell acute lymphoblastic leukemia (T-ALL) is a serious blood cancer, particularly in children, and current treatments, while improving, still face challenges with drug resistance and relapse. This means there's a critical need to understand the underlying mechanisms driving T-ALL to develop more effective, targeted therapies. Autophagy, a cellular recycling process, is known to play a complex role in cancer, but its specific involvement in T-ALL has remained unclear. This paper aims to shed light on this by investigating the role of autophagy-related genes, specifically ATG4B, and its interaction with other key players in T-ALL development.

Methods

The study employed a multi-pronged approach:

  • RT-qPCR: Used to measure the expression levels of various autophagy-related genes in T-ALL patient cells and normal controls.
  • Gene Silencing and Overexpression: Techniques like shRNA and lentiviral vectors were used to reduce or increase the expression of ATG4B and SESN3 to study their functional impact.
  • CRISPR/Cas9: Employed for precise gene editing to knock out ATG4B in T-ALL cells.
  • Animal Models: Atg4b-deficient mice were used to assess the role of ATG4B in normal hematopoiesis and T-cell development. Xenograft models with human T-ALL cells were created to evaluate the anti-leukemic efficacy of an ATG4B inhibitor.
  • Western Blotting: Used to analyze protein levels and signaling pathways (e.g., mTOR, AMPK, S6K).
  • RNA-sequencing (RNA-seq): Performed to identify global changes in gene expression upon ATG4B silencing.
  • Flow Cytometry: Utilized for cell analysis, including immune cell profiling and assessing leukemic cell infiltration in animal models.
  • Puromycin Incorporation Assay: A method to measure protein synthesis rates.
  • Luciferase Reporter Assays: Used to investigate the transcriptional regulation of SESN3.

Datasets

  • Primary Patient Samples: Bone marrow cells from T-ALL patients and normal bone marrow (NBM) cells from healthy donors were used for RT-qPCR and other analyses.
  • Public Databases: Gene Expression Omnibus (GEO) datasets (GSE13159, GSE26713) were utilized for comparative gene expression analysis.
  • Cell Lines: Jurkat, MOLT-4, CCRF-CEM, and 293T cell lines were used for in vitro experiments.

Key Insights and Ideas

  • ATG4B as a Key Player: The study strongly implicates ATG4B as a central figure in T-ALL, showing its significantly elevated expression in leukemic cells and its crucial role in promoting their growth and survival.
  • Autophagy's Dual Role: While autophagy is generally considered a survival mechanism, the paper highlights how dysregulation of ATG4B can lead to increased autophagy activity that paradoxically fuels T-ALL.
  • The ATG4B-SESN3 Axis: A novel regulatory circuit is revealed where ATG4B silencing leads to increased SESN3 expression. This interaction is critical, as SESN3 acts as a tumor suppressor by inhibiting key growth pathways.
  • SESN3 as a Tumor Suppressor: SESN3 is identified as a novel tumor suppressor in T-ALL, working by inhibiting the mTOR signaling pathway and autophagy.
  • Targeting ATG4B for Therapy: The development and testing of an ATG4B inhibitor (S130) demonstrate its potential as an effective therapeutic agent against T-ALL, showing significant anti-leukemic activity in both cell lines and animal models.

Key Results

  • Elevated ATG4B in T-ALL: T-ALL patient cells showed significantly higher expression of ATG4B compared to normal cells.
  • ATG4B Silencing Inhibits Growth: Reducing ATG4B levels in T-ALL cells significantly inhibited their growth and colony-forming ability, both in vitro and in vivo.
  • ATG4B Depletion's Mild Effect on Normal Cells: In contrast to its impact on T-ALL cells, Atg4b deficiency had only mild effects on normal hematopoiesis and T-cell development in mice.
  • SESN3 Upregulation upon ATG4B Loss: Silencing ATG4B led to a significant increase in SESN3 expression in T-ALL cells.
  • ATG4B Inhibitor Efficacy: The ATG4B inhibitor S130 demonstrated significant anti-leukemic activity, prolonging survival in xenograft mouse models and reducing leukemic cell infiltration.
  • SESN3's Tumor-Suppressing Role: Overexpression of SESN3 inhibited T-ALL cell growth and colony formation, while SESN3 silencing shortened survival in a xenograft model.

Limitations and Future Work

  • Atg4b Deficiency in Mice: While Atg4b knockout mice were viable, their effects on normal hematopoiesis and T-cell development were subtle and require further investigation, particularly regarding observed opposite effects on B220+ and Ter119+ cells in peripheral blood.
  • SESN3's Autophagy Regulation: The study noted a discrepancy where SESN3's effect on autophagy activity seemed incompatible with the concept of mTOR inhibition leading to autophagy activation. Further research is needed to fully elucidate this complex interaction.
  • Therapeutic Translation: While S130 showed promise, further studies are needed to assess its safety and efficacy in more complex preclinical models and eventually in clinical trials.
  • EGR1's Role: The identification of EGR1 as a key transcriptional regulator of SESN3 upon ATG4B blockade is a significant finding, but its precise role and downstream targets warrant deeper exploration.

Summary updated

Abstract

The present study demonstrates that a novel ATG4B-SESN3 regulatory circuit plays a crucial role in T cell leukemogenesis, which suggests that targeting ATG4B is a promising strategy for T-ALL treatment.
BibTeX
@article{ma2025novel,
  author = {Wenjuan Ma and Lei Zhang and Haixia Zhou and Xiuyan Zhang and Xiao Qin and Yan Wan and Rongyao Ma and Xiang Song and Xiaonan Zhou and Hong Liu and Bo Hu and Depei Wu and Jianrong Wang and Xiaoyan Jiang and Yun Zhao},
  title = {{A novel regulatory circuit of ATG4B and SESN3 promotes T cell leukemogenesis}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2025},
  doi = {10.1186/s13046-025-03588-0},
}
Figure